KQED Nightly Business Report July 13, 2024
Off. It was a busy earnings day dominated by corporate news. And we begin with something no one saw coming. Biotech firm biogen surprised investors when it said the experimental alzheimers treatment was ready for the Regulatory Approval press. As you may recall, seven months ago the company discontinued the study of the drug which some expected to be the next blockbuster. Analysts say the profit potential is huge because there are no current therapies to reverse affects of the disease. A disease affecting millions and projected to affect millions more in the years to come. The news sent smars ...